Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA.
Yale School of Public Health, New Haven, CT, USA.
Cancer Invest. 2023 Sep;41(7):646-655. doi: 10.1080/07357907.2023.2242957. Epub 2023 Aug 17.
Preclinical data suggest that mutations result in defective homologous recombination repair (HRR). We hypothesized that patients with mt intrahepatic cholangiocarcinoma (IHCC) would benefit more from 1 L platinum chemotherapy than patients with wildtype (WT) tumors. We performed a multicenter retrospective study of 81 patients with unresectable IHCC treated with 1 L platinum with a primary endpoint of clinical benefit rate (CBR). Patients with mt tumors had a similar CBR and objective response rate compared to those with WT disease (59 versus 54%; = 0.803), suggesting that a relationship between platinum sensitivity and HRR gene defects may be specific to tumor context.
临床前数据表明， 突变导致同源重组修复（HRR）缺陷。我们假设，与野生型（WT）肿瘤患者相比，患有 mt 肝内胆管癌（IHCC）的患者将从 1 升铂化疗中获益更多。我们对 81 例接受 1 升铂化疗的不可切除 IHCC 患者进行了多中心回顾性研究，主要终点为临床获益率（CBR）。与 WT 疾病患者相比，mt 肿瘤患者的 CBR 和客观缓解率相似（59%对 54%； = 0.803），这表明铂敏感性与 HRR 基因缺陷之间的关系可能特定于肿瘤背景。
Zotero 插件